Previous close | 3.4000 |
Open | 2.0900 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 220.00 |
Expiry date | 2025-06-20 |
Day's range | 1.7500 - 3.4000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Discover how Vertex Pharmaceuticals Inc achieved significant financial and operational milestones in the first quarter of 2024.
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives